Development & Aseptic Production of Drug Products

Immune Targeting Systems (ITS) Limited is a Londonbased Biotech Company developing synthetic vaccines for mutating viruses. Their proprietary vaccine technology relies on highly selected long peptides containing protective T cell epitopes modified with a fluorocarbon vector. Designed as a stable freezedried formulation, the vaccine delivers the antigens into the body to promote robust T-cell immunity without requiring potentially toxic adjuvants. ITS’ lead candidate is a universal influenza-A vaccine containing multiple fluoropeptides.